CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
Pentoxifyllinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000646
NCT00000646Phase 1Completed
CompareCT.gov

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 2, 2021

In Brief

A Phase 1 clinical trial evaluating Pentoxifylline for HIV Infections. Completed, across 2 sites.

Detailed Summary

To determine whether pentoxifylline lowers tumor necrosis factor (TNF) levels in AIDS patients. Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of zidovudine (AZT) activity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsHoechst Marion Roussel

Timeline

Phase 1CompletedFinished
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionMar 1, 1993
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Pentoxifyllinedrug